Stock DCPH DECIPHERA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Deciphera Pharmaceuticals, Inc.

Equities

DCPH

US24344T1016

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 11:48:32 01/05/2024 pm IST 		5-day change 1st Jan Change
25.36 USD +0.38% Intraday chart for Deciphera Pharmaceuticals, Inc. +73.26% +57.04%
12:13pm North American Morning Briefing : Traders Wait for -2- DJ
30/04 Barclays Upgrades Deciphera Pharmaceuticals to Equalweight From Underweight, Price Target is $26 MT

Business Summary

Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing new medicines to improve the lives of people with cancer. The Company is leveraging its switch-control kinase inhibitor platform in kinase biology to develop a portfolio of medicines. The Company's QINLOCK, is a switch-control kinase inhibitor, engineered using its drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor (GIST). In addition to QINLOCK, it has developed a robust pipeline of drug candidates using its switch-control kinase inhibitor platform, including vimseltinib and DCC-3116. Vimseltinib is an investigational, orally administered, potent, and highly-selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) kinase for the potential treatment of tenosynovial giant cell tumor (TGCT). DCC-3116 is a Phase 1/2 inhibitor of ULK kinases being developed to inhibit autophagy.

Number of employees: 355

Sales per Business

USD in Million2022Weight2023Weight Delta
Switch Control Kinase Inhibitor Platform
100.0 %
126 100.0 % 159 100.0 % +26.75%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
76.4 %
97 77.5 % 122 76.4 % +25.03%
Rest of World
12.3 %
14 11.1 % 20 12.3 % +39.91%
Germany
11.3 %
14 11.4 % 18 11.3 % +25.58%

Managers

Managers TitleAgeSince
Steven Hoerter CEO
 Chief Executive Officer 53 17/18/17
Tucker Kelly DFI
 Director of Finance/CFO 53 01/15/01
Kevin Brodbeck CTO
 Chief Tech/Sci/R&D Officer - 01/23/01
Rodrigo Ruiz Soto CTO
 Chief Tech/Sci/R&D Officer - 01/17/01
Dashyant Dhanak CTO
 Chief Tech/Sci/R&D Officer 63 05/23/05
Matthew Sherman CTO
 Chief Tech/Sci/R&D Officer 68 02/19/02
Lisa Amaya Price HRO
 Human Resources Officer - 01/22/01
Kelley Dealhoy PRN
 Corporate Officer/Principal - 16/22/16
Jama Pitman PRN
 Corporate Officer/Principal 45 01/15/01
Daniel Martin PRN
 Corporate Officer/Principal 49 18/18/18

Members of the board

Members of the board TitleAgeSince
Patricia Allen BRD
 Director/Board Member 62 01/16/01
Edward Benz BRD
 Director/Board Member 78 01/19/01
Ron Squarer CHM
 Chairman 57 04/19/04
John R. Martin BRD
 Director/Board Member 63 01/15/01
James Bristol BRD
 Director/Board Member 77 01/07/01
Susan Kelley BRD
 Director/Board Member 69 08/19/08
Steven Hoerter CEO
 Chief Executive Officer 53 17/18/17
Dennis Walsh BRD
 Director/Board Member 56 01/15/01
Franklin Friedman BRD
 Director/Board Member 66 01/19/01

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 82,225,972 57,541,331 ( 69.98 %) 0 69.98 %

Shareholders

NameEquities%Valuation
Brightstar Associates LLC
28.60 %
23,107,844 28.60 % 363 M $
Deerfield Management Co. LP (Private Equity)
7.163 %
5,788,024 7.163 % 91 M $
BlackRock Advisors LLC
6.889 %
5,566,249 6.889 % 88 M $
Armistice Capital LLC
6.436 %
5,200,000 6.436 % 82 M $
Redmile Group LLC
5.942 %
4,801,540 5.942 % 76 M $
Vanguard Fiduciary Trust Co.
5.448 %
4,401,636 5.448 % 69 M $
STATE STREET CORPORATION
3.058 %
2,470,813 3.058 % 39 M $
Morgan Stanley Investment Management, Inc.
2.867 %
2,316,433 2.867 % 36 M $
Goldman Sachs Asset Management LP
2.856 %
2,307,475 2.856 % 36 M $
POLAR CAPITAL HOLDINGS PLC
2.290 %
1,850,000 2.290 % 29 M $

Company contact information

Deciphera Pharmaceuticals, Inc.

200 Smith Street

02451, Waltham

+781 209 6400

http://www.deciphera.com
address Deciphera Pharmaceuticals, Inc.(DCPH)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per region

Ratings for Deciphera Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
25.27 USD
Average target price
26.38 USD
Spread / Average Target
+4.38%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
DECIPHERA PHARMACEUTICALS, INC. Stock Deciphera Pharmaceuticals, Inc.
+57.04% 2.08B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.74% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.22% 96.09B
ARGENX SE Stock argenx SE
+2.13% 22.28B
BIONTECH SE Stock BioNTech SE
-16.76% 21.4B
GENMAB A/S Stock Genmab A/S
-8.79% 18.14B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.02B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.89% 16.09B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.09% 13.83B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.36% 11.97B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. DCPH Stock
  4. Company Deciphera Pharmaceuticals, Inc.